Author/Authors :
Stevens, Wendy Department of Molecular Medicine and Haematology - Faculty of Health Sciences - School of Pathology - University of the Witwatersrand - Johannesburg, South Africa , Chikaonda, Tarsizio Department of Molecular Medicine and Haematology - Faculty of Health Sciences - School of Pathology - University of the Witwatersrand - Johannesburg, South Africa , Scott, Lesley Department of Molecular Medicine and Haematology - Faculty of Health Sciences - School of Pathology - University of the Witwatersrand - Johannesburg, South Africa , Nguluwe, Nelson University of North Carolina Project - Lilongwe, Malawi , Barnett, Brian University of North Carolina Project - Lilongwe, Malawi , Gokhale, Runa H. University of North Carolina Project - Lilongwe, Malawi , Krysiak, Robert University of North Carolina Project - Lilongwe, Malawi , Thengolose, Isaac University of North Carolina Project - Lilongwe, Malawi , Rosenberg, Nora E. University of North Carolina Project - Lilongwe, Malawi , Stanley, Christopher University of North Carolina Project - Lilongwe, Malawi , Hoffman, Irving F. University of North Carolina Project - Lilongwe, Malawi , Hosseinipour, Mina University of North Carolina Project - Lilongwe, Malawi , Mpunga, James Malawi National Tuberculosis Programme - Lilongwe, Malawi
Abstract :
Xpert® MTB/RIF is a molecular test for the detection of Mycobacterium tuberculosis and rifampicin resistance. It is considered to be a great advance over smear microscopy and culture. However, there is very little information regarding the performance characteristics of Xpert MTB/RIF in Malawi.
Objective
We aimed to evaluate the performance of Xpert MTB/RIF in a Malawian setting.
Methods
Stored sputum pellets were processed on Xpert MTB/RIF between June 2012 and May 2014. Results were compared to mycobacteria growth indicator tube and Löwenstein-Jensen cultures, LED fluorescent microscopy and GenoType® MTBDRplus assay. Rifampicin resistance was confirmed by DNA sequencing.
Results
Of the 348 specimens with valid Xpert MTB/RIF results, 129/348 (37%) were smear-positive and 198/348 (57%) were culture-positive. Xpert MTB/RIF demonstrated a sensitivity of 93.8% (95% CI 89.4% – 96.8%) and specificity of 97.4% (95% CI 93.5% – 99.3%), with a positive predictive value of 97.8% (95% CI 94.6% – 99.4%) and a negative predictive value of 92.6% (95% CI 87.4% – 96.1%). Xpert MTB/RIF correctly identified 185/186 (99.5%) rifampicin-sensitive and 2/2 (100%) rifampicin-resistant M. tuberculosis strains. Mutations were not detected by sequencing in one isolate which was rifampicin resistant on Xpert MTB/RIF but sensitive on MTBDRplus. Four non-tuberculous mycobacteria grew from four smear-negative specimens, namely, M. avium (n = 1) and M. intracellulare (n = 3). No cross-reactivity was observed with any of the non-tuberculous mycobacteria when using Xpert MTB/RIF.
Conclusion
When fully implemented, Xpert MTB/RIF may have an impact on patient care in Malawi. The increased diagnostic yield of Xpert MTB/RIF over smear microscopy can increase laboratory-confirmed tuberculosis detection and ensure that treatment is given to appropriate individuals or groups.
Keywords :
Performance , Xpert MTB / RIF , tuberculosis outpatients , Lilongwe , Malawi , MDR , HIV
